naltrexone and bupropion
Contrave (bupropion and naltrexone) is apparently unique. The SEC disclosed that the US patent office gave the 371 patent to Orexigen Therapeutics based on an interim look at the LIGHT study. What this means is that Contrave has a claim for having a POSITIVE IMPACT on cardiovascular results (outcomes) beyond (unrelated to) weight loss.
More to come and most probably from the American College of Cardiology meeting in San Diego this month. Regardless, having strength in weight loss AND HEART disease is a true breakthrough in medicines.
Weight loss medicines have not had such a good track record recently when being considered by the FDA. Yet another candidate is named Contrave and is a combination of two medicines (bupropion SR and naltrexone SR) in a single pill. The FDA expert advisory panel (Endocrine and Metabolic committee) will meet to consider this combination pill in December.